Literature DB >> 23572558

Constitutively active ALK2 receptor mutants require type II receptor cooperation.

Jana Bagarova1, Ashley J Vonner, Kelli A Armstrong, Jan Börgermann, Carol S C Lai, Donna Y Deng, Hideyuki Beppu, Ivan Alfano, Panagis Filippakopoulos, Nicholas W Morrell, Alex N Bullock, Petra Knaus, Yuji Mishina, Paul B Yu.   

Abstract

Constitutively activating mutations in receptor kinases recruit downstream effector pathways independently of upstream signaling, with consequences ranging from developmental syndromes to cancer. Classic fibrodysplasia ossificans progressiva (FOP) is a congenital syndrome resulting from highly conserved activating mutations of the glycine-serine-rich (GS) regulatory domain of ACVR1, encoding bone morphogenetic protein (BMP) type I receptor ALK2, which lead to inappropriate signaling and heterotopic ossification of soft tissues. It is unclear if constitutively active mutant ALK2 receptors (caALK2) can function independently of signaling complexes with type II receptors and ligands. We found that ablation of BmpRII and ActRIIa abrogated BMP ligand-mediated and caALK2-mediated signaling and transcription in cells and disrupted caALK2-induced heterotopic ossification in mice. Signaling via GS domain ALK2 mutants could be restored by the expression of either BMP type II receptor. The contribution of BMP type II receptors was independent of their ligand-binding or kinase function but was dependent upon an intact cytoplasmic domain. These data demonstrate that GS domain ALK2 mutants act independently of upstream signaling but may require a nonenzymatic scaffolding function provided by type II receptors to form functional, apparently ligand-independent signaling complexes. These findings define the minimal requirements for signaling of GS domain ALK2 mutants, with implications for the therapeutic targeting of their activity in disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572558      PMCID: PMC3700091          DOI: 10.1128/MCB.01595-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  28 in total

1.  The type II activin receptors are essential for egg cylinder growth, gastrulation, and rostral head development in mice.

Authors:  J Song; S P Oh; H Schrewe; M Nomura; H Lei; M Okano; T Gridley; E Li
Journal:  Dev Biol       Date:  1999-09-01       Impact factor: 3.582

2.  The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways.

Authors:  Anja Nohe; Sylke Hassel; Marcelo Ehrlich; Florian Neubauer; Walter Sebald; Yoav I Henis; Petra Knaus
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

3.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

Review 4.  Constitutively active receptors as a disease-causing mechanism.

Authors:  J Parma; L Duprez; J Van Sande; R Paschke; M Tonacchera; J Dumont; G Vassart
Journal:  Mol Cell Endocrinol       Date:  1994-04       Impact factor: 4.102

5.  Generation of a floxed allele of the mouse BMP type II receptor gene.

Authors:  Hideyuki Beppu; Hong Lei; Kenneth D Bloch; En Li
Journal:  Genesis       Date:  2005-03       Impact factor: 2.487

6.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.

Authors:  Nung Rudarakanchana; Julia A Flanagan; Hailan Chen; Paul D Upton; Rajiv Machado; D Patel; Richard C Trembath; Nicholas W Morrell
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

7.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

Authors:  P Schuck
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

8.  BMP signaling is required for septation of the outflow tract of the mammalian heart.

Authors:  Emmanuèle C Délot; Matthew E Bahamonde; Manxu Zhao; Karen M Lyons
Journal:  Development       Date:  2003-01       Impact factor: 6.868

9.  Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.

Authors:  M Macías-Silva; P A Hoodless; S J Tang; M Buchwald; J L Wrana
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

10.  Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4.

Authors:  P ten Dijke; H Yamashita; T K Sampath; A H Reddi; M Estevez; D L Riddle; H Ichijo; C H Heldin; K Miyazono
Journal:  J Biol Chem       Date:  1994-06-24       Impact factor: 5.157

View more
  38 in total

Review 1.  Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.

Authors:  Emilie Barruet; Edward C Hsiao
Journal:  Bone       Date:  2017-07-14       Impact factor: 4.398

Review 2.  Stem cells and heterotopic ossification: Lessons from animal models.

Authors:  John B Lees-Shepard; David J Goldhamer
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

3.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

4.  Apyrase as a novel therapeutic inhibitor of heterotopic ossification.

Authors:  Olin D Liang; Anthony M Reginato; Damian Medici
Journal:  Ann Transl Med       Date:  2015-05

Review 5.  Activin receptor-like kinases: a diverse family playing an important role in cancer.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

Review 6.  Signaling Receptors for TGF-β Family Members.

Authors:  Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

7.  Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Makoto Ikeya; Kazuhiko Horigome; Yoshihisa Matsumoto; Hayao Ebise; Megumi Nishio; Kazuya Sekiguchi; Mitsuaki Shibata; Sanae Nagata; Shuichi Matsuda; Junya Toguchida
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

Review 8.  Molecular and cellular mechanisms of heterotopic ossification.

Authors:  Diana M Ramirez; Melissa R Ramirez; Anthony M Reginato; Damian Medici
Journal:  Histol Histopathol       Date:  2014-05-05       Impact factor: 2.303

9.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

Review 10.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.